Cargando…

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases

PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Romei, Cristina, Ciampi, Raffaele, Casella, Francesca, Tacito, Alessia, Torregrossa, Liborio, Ugolini, Clara, Basolo, Fulvio, Materazzi, Gabriele, Vitti, Paolo, Elisei, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839408/
https://www.ncbi.nlm.nih.gov/pubmed/29515777
http://dx.doi.org/10.18632/oncotarget.23986
_version_ 1783304405469102080
author Romei, Cristina
Ciampi, Raffaele
Casella, Francesca
Tacito, Alessia
Torregrossa, Liborio
Ugolini, Clara
Basolo, Fulvio
Materazzi, Gabriele
Vitti, Paolo
Elisei, Rossella
author_facet Romei, Cristina
Ciampi, Raffaele
Casella, Francesca
Tacito, Alessia
Torregrossa, Liborio
Ugolini, Clara
Basolo, Fulvio
Materazzi, Gabriele
Vitti, Paolo
Elisei, Rossella
author_sort Romei, Cristina
collection PubMed
description PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the corresponding metastatic tissues in a series of advanced metastatic cases. RESULTS: This study demonstrated that in about 20% of cases a different RET mutation profile can be found when comparing primary tumor and its corresponding metastases. Furthermore in 8% of tumors, RET intratumor heterogeneity was observed We also showed that in some cases an imbalance of RET copy number was present. We confirmed a high prevalence (90%) of RET somatic mutations in advanced tumors. MATERIALS AND METHODS: Fifty-six MTC patients (50 somatic and 6 hereditary cases) have been included in the study and a total of 209 specimens have been analysed by direct sequencing. Multiplex ligation-dependent probe amplification (MLPA) has been used to investigate amplification/deletion of RET alleles. CONCLUSIONS: In conclusion, this study showed a genetic intra- and intertumor heterogeneity in MTC, But in only 20% of CASES These results could justify the relatively moderate level of aggressiveness of the disease with respect to more aggressive human tumors that are characterized by a high rate of mutation and heterogeneity.
format Online
Article
Text
id pubmed-5839408
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58394082018-03-07 RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases Romei, Cristina Ciampi, Raffaele Casella, Francesca Tacito, Alessia Torregrossa, Liborio Ugolini, Clara Basolo, Fulvio Materazzi, Gabriele Vitti, Paolo Elisei, Rossella Oncotarget Research Paper PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the corresponding metastatic tissues in a series of advanced metastatic cases. RESULTS: This study demonstrated that in about 20% of cases a different RET mutation profile can be found when comparing primary tumor and its corresponding metastases. Furthermore in 8% of tumors, RET intratumor heterogeneity was observed We also showed that in some cases an imbalance of RET copy number was present. We confirmed a high prevalence (90%) of RET somatic mutations in advanced tumors. MATERIALS AND METHODS: Fifty-six MTC patients (50 somatic and 6 hereditary cases) have been included in the study and a total of 209 specimens have been analysed by direct sequencing. Multiplex ligation-dependent probe amplification (MLPA) has been used to investigate amplification/deletion of RET alleles. CONCLUSIONS: In conclusion, this study showed a genetic intra- and intertumor heterogeneity in MTC, But in only 20% of CASES These results could justify the relatively moderate level of aggressiveness of the disease with respect to more aggressive human tumors that are characterized by a high rate of mutation and heterogeneity. Impact Journals LLC 2018-01-04 /pmc/articles/PMC5839408/ /pubmed/29515777 http://dx.doi.org/10.18632/oncotarget.23986 Text en Copyright: © 2018 Romei et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Romei, Cristina
Ciampi, Raffaele
Casella, Francesca
Tacito, Alessia
Torregrossa, Liborio
Ugolini, Clara
Basolo, Fulvio
Materazzi, Gabriele
Vitti, Paolo
Elisei, Rossella
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title_full RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title_fullStr RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title_full_unstemmed RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title_short RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
title_sort ret mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839408/
https://www.ncbi.nlm.nih.gov/pubmed/29515777
http://dx.doi.org/10.18632/oncotarget.23986
work_keys_str_mv AT romeicristina retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT ciampiraffaele retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT casellafrancesca retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT tacitoalessia retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT torregrossaliborio retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT ugoliniclara retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT basolofulvio retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT materazzigabriele retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT vittipaolo retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases
AT eliseirossella retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases